



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. SERIAL NO. : 10/729,704
APPLICANTS : Guenzler-Pukall, et al.
FILING DATE : 04 December 2003
EXAMINER : Roy R. Teller
GROUP ART UNIT : 1654
DOCKET NO. : FP0602.1 US
TITLE : TREATMENT OF DIABETES

Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

**NOTICE OF APPEAL FROM THE EXAMINER TO THE BOARD
OF PATENT APPEALS AND INTERFERENCES**

Sir:

Applicant hereby appeals to the Board of Patent Appeals and Interferences from the last decision of the Examiner in the Final Office Action dated 23 September 2009, in which claims 43-56 were rejected, in the above-identified patent application.

Applicants claim small entity status under 37 C.F.R. 1.27.

The Commissioner is hereby authorized to charge the total of the Notice of Appeal fee to Deposit Account No. 50-0811, referencing Docket No. FP0602.1 US.

Please call Applicants' representative at 415-978-1742 with any questions regarding this communication or the above-identified patent.

Respectfully submitted,

Date: 23 March 2010

By:

Christopher T. Jacob
Christopher T. Jacob
Reg. No. 59,938

FibroGen, Inc.
409 Illinois Street
San Francisco CA 94158
Main: 415-978-1200
Direct: 415-978-1742
Facsimile: 415-978-1917
cjacob@fibrogen.com

Certificate of mailing or transmission under 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 23 March 2010.

Name: Michael Moores

Signature: Michael Moores

03/29/2010 HDESTAR 00000044 500811 10729704

01 FC:2401 270.00 DA